Which drug better protects GCA patients from heart attacks and strokes?
NCT ID NCT07459335
First seen Mar 12, 2026 · Last updated May 21, 2026 · Updated 14 times
Summary
This study looked at two medications, tocilizumab and methotrexate, to see which one better prevents major heart problems like heart attacks, strokes, or death in people with giant cell arteritis (GCA). Researchers analyzed data from over 1,600 patients in France who were newly treated with one of these drugs. The goal was to find out which treatment offers better protection for the heart and blood vessels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP_ Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
APHP_ Hôpital Saint-Antoine
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.